Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Defining estrogenic mechanisms of bisphenol A analogs through high throughput microscopy-based contextual assays.

Stossi F, Bolt MJ, Ashcroft FJ, Lamerdin JE, Melnick JS, Powell RT, Dandekar RD, Mancini MG, Walker CL, Westwick JK, Mancini MA.

Chem Biol. 2014 Jun 19;21(6):743-53. doi: 10.1016/j.chembiol.2014.03.013. Epub 2014 May 22.

2.

Improving drug discovery with contextual assays and cellular systems analysis.

Westwick JK, Lamerdin JE.

Methods Mol Biol. 2011;756:61-73. doi: 10.1007/978-1-61779-160-4_3. Review.

PMID:
21870220
3.

Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.

Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, Lamerdin J, Dagostino E, Knighton D, Loi CM, Zager M, Kraynov E, Popoff I, Christensen JG, Martinez R, Kephart SE, Marakovits J, Karlicek S, Bergqvist S, Smeal T.

Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51. doi: 10.1073/pnas.0911863107. Epub 2010 May 3.

4.

Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase.

Ding Z, Liang J, Li J, Lu Y, Ariyaratna V, Lu Z, Davies MA, Westwick JK, Mills GB.

PLoS One. 2010 Mar 26;5(3):e9910. doi: 10.1371/journal.pone.0009910.

5.

Fluorescent protein-based cellular assays analyzed by laser-scanning microplate cytometry in 1536-well plate format.

Auld DS, Johnson RL, Zhang YQ, Veith H, Jadhav A, Yasgar A, Simeonov A, Zheng W, Martinez ED, Westwick JK, Austin CP, Inglese J.

Methods Enzymol. 2006;414:566-89.

PMID:
17110211
6.

Chemical genetic strategies to delineate MAP kinase signaling pathways using protein-fragment complementation assays (PCA).

Michnick SW, MacDonald ML, Westwick JK.

Methods. 2006 Nov;40(3):287-93. Review.

PMID:
17071407
7.

Exploiting network biology to improve drug discovery.

MacDonald ML, Westwick JK.

Methods Mol Biol. 2007;356:221-32.

PMID:
16988406
8.

Protein-fragment complementation assays (PCA) in small GTPase research and drug discovery.

Westwick JK, Michnick SW.

Methods Enzymol. 2006;407:388-401.

PMID:
16757340
9.

Identifying off-target effects and hidden phenotypes of drugs in human cells.

MacDonald ML, Lamerdin J, Owens S, Keon BH, Bilter GK, Shang Z, Huang Z, Yu H, Dias J, Minami T, Michnick SW, Westwick JK.

Nat Chem Biol. 2006 Jun;2(6):329-37. Epub 2006 May 7.

PMID:
16680159
10.

JNK mediates hepatic ischemia reperfusion injury.

Uehara T, Bennett B, Sakata ST, Satoh Y, Bilter GK, Westwick JK, Brenner DA.

J Hepatol. 2005 Jun;42(6):850-9. Epub 2005 Apr 7.

PMID:
15885356
11.
12.

Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase.

Ennis BW, Fultz KE, Smith KA, Westwick JK, Zhu D, Boluro-Ajayi M, Bilter GK, Stein B.

J Pharmacol Exp Ther. 2005 Apr;313(1):325-32. Epub 2004 Dec 30.

PMID:
15626722
13.

Measuring drug action in the cellular context using protein-fragment complementation assays.

Yu H, West M, Keon BH, Bilter GK, Owens S, Lamerdin J, Westwick JK.

Assay Drug Dev Technol. 2003 Dec;1(6):811-22.

PMID:
15090227
14.

Therapeutic modulation of inflammatory gene transcription by kinase inhibitors.

Alton G, Schwamborn K, Satoh Y, Westwick JK.

Expert Opin Biol Ther. 2002 Aug;2(6):621-32. Review.

PMID:
12171506
15.

Raf-independent deregulation of p38 and JNK mitogen-activated protein kinases are critical for Ras transformation.

Pruitt K, Pruitt WM, Bilter GK, Westwick JK, Der CJ.

J Biol Chem. 2002 Aug 30;277(35):31808-17. Epub 2002 Jun 24.

16.

Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle.

Mettouchi A, Klein S, Guo W, Lopez-Lago M, Lemichez E, Westwick JK, Giancotti FG.

Mol Cell. 2001 Jul;8(1):115-27.

17.

Functional proteomics analysis of GTPase signaling networks.

Alton G, Cox AD, Toussaint LG 3rd, Westwick JK.

Methods Enzymol. 2001;332:300-16. No abstract available.

PMID:
11305106
18.

Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway.

Joyce D, Bouzahzah B, Fu M, Albanese C, D'Amico M, Steer J, Klein JU, Lee RJ, Segall JE, Westwick JK, Der CJ, Pestell RG.

J Biol Chem. 1999 Sep 3;274(36):25245-9.

19.

Oncogenic ras induces gastrin gene expression in colon cancer.

Nakata H, Wang SL, Chung DC, Westwick JK, Tillotson LG.

Gastroenterology. 1998 Nov;115(5):1144-53.

PMID:
9797369
20.
21.

Mas oncogene signaling and transformation require the small GTP-binding protein Rac.

Zohn IE, Symons M, Chrzanowska-Wodnicka M, Westwick JK, Der CJ.

Mol Cell Biol. 1998 Mar;18(3):1225-35.

22.

Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K.

Keely PJ, Westwick JK, Whitehead IP, Der CJ, Parise LV.

Nature. 1997 Dec 11;390(6660):632-6.

PMID:
9403696
23.

Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation.

Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin AS Jr.

J Biol Chem. 1997 Sep 26;272(39):24113-6.

24.

L-glutamine stimulates intestinal cell proliferation and activates mitogen-activated protein kinases.

Rhoads JM, Argenzio RA, Chen W, Rippe RA, Westwick JK, Cox AD, Berschneider HM, Brenner DA.

Am J Physiol. 1997 May;272(5 Pt 1):G943-53.

PMID:
9176200
25.

The coupling of alpha6beta4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation.

Mainiero F, Murgia C, Wary KK, Curatola AM, Pepe A, Blumemberg M, Westwick JK, Der CJ, Giancotti FG.

EMBO J. 1997 May 1;16(9):2365-75.

26.

Lck regulates Vav activation of members of the Rho family of GTPases.

Han J, Das B, Wei W, Van Aelst L, Mosteller RD, Khosravi-Far R, Westwick JK, Der CJ, Broek D.

Mol Cell Biol. 1997 Mar;17(3):1346-53.

27.

Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways.

Westwick JK, Lambert QT, Clark GJ, Symons M, Van Aelst L, Pestell RG, Der CJ.

Mol Cell Biol. 1997 Mar;17(3):1324-35.

28.

p120 GAP modulates Ras activation of Jun kinases and transformation.

Clark GJ, Westwick JK, Der CJ.

J Biol Chem. 1997 Jan 17;272(3):1677-81.

29.

Isolation of a NCK-associated kinase, PRK2, an SH3-binding protein and potential effector of Rho protein signaling.

Quilliam LA, Lambert QT, Mickelson-Young LA, Westwick JK, Sparks AB, Kay BK, Jenkins NA, Gilbert DJ, Copeland NG, Der CJ.

J Biol Chem. 1996 Nov 15;271(46):28772-6.

30.

Differential regulation of hepatocyte DNA synthesis by cAMP in vitro in vivo.

Westwick JK, Fleckenstein J, Yin M, Yang SQ, Bradham CA, Brenner DA, Diehl AM.

Am J Physiol. 1996 Nov;271(5 Pt 1):G780-90.

PMID:
8944691
31.

Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation.

Khosravi-Far R, White MA, Westwick JK, Solski PA, Chrzanowska-Wodnicka M, Van Aelst L, Wigler MH, Der CJ.

Mol Cell Biol. 1996 Jul;16(7):3923-33.

32.

Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation.

Galang CK, García-Ramírez J, Solski PA, Westwick JK, Der CJ, Neznanov NN, Oshima RG, Hauser CA.

J Biol Chem. 1996 Apr 5;271(14):7992-8.

33.

L-glutamine and L-asparagine stimulate ODC activity and proliferation in a porcine jejunal enterocyte line.

Kandil HM, Argenzio RA, Chen W, Berschneider HM, Stiles AD, Westwick JK, Rippe RA, Brenner DA, Rhoads JM.

Am J Physiol. 1995 Oct;269(4 Pt 1):G591-9.

PMID:
7485512
34.

Ceramide activates the stress-activated protein kinases.

Westwick JK, Bielawska AE, Dbaibo G, Hannun YA, Brenner DA.

J Biol Chem. 1995 Sep 29;270(39):22689-92.

35.

Insulin-like growth factor-I and epidermal growth factor interact to regulate growth and gene expression in IEC-6 intestinal epithelial cells.

Simmons JG, Hoyt EC, Westwick JK, Brenner DA, Pucilowska JB, Lund PK.

Mol Endocrinol. 1995 Sep;9(9):1157-65.

PMID:
7491108
36.

Activation of Jun kinase is an early event in hepatic regeneration.

Westwick JK, Weitzel C, Leffert HL, Brenner DA.

J Clin Invest. 1995 Feb;95(2):803-10.

37.

Ras-mediated transcription activation: analysis by transient cotransfection assays.

Hauser CA, Westwick JK, Quilliam LA.

Methods Enzymol. 1995;255:412-26. No abstract available.

PMID:
8524127
38.

Methods for analyzing c-Jun kinase.

Westwick JK, Brenner DA.

Methods Enzymol. 1995;255:342-59. No abstract available.

PMID:
8524120
39.

Tumor necrosis factor alpha stimulates AP-1 activity through prolonged activation of the c-Jun kinase.

Westwick JK, Weitzel C, Minden A, Karin M, Brenner DA.

J Biol Chem. 1994 Oct 21;269(42):26396-401.

40.

The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation.

Cox AD, Garcia AM, Westwick JK, Kowalczyk JJ, Lewis MD, Brenner DA, Der CJ.

J Biol Chem. 1994 Jul 29;269(30):19203-6.

41.

Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases.

Westwick JK, Cox AD, Der CJ, Cobb MH, Hibi M, Karin M, Brenner DA.

Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6030-4.

42.

Activation of activating protein 1 during hepatic acute phase response.

Hattori M, Tugores A, Westwick JK, Veloz L, Leffert HL, Karin M, Brenner DA.

Am J Physiol. 1993 Jan;264(1 Pt 1):G95-103.

PMID:
8430810

Supplemental Content

Loading ...
Support Center